Abstract | BACKGROUND/OBJECTIVES: DESIGN/METHODS: A retrospective chart review was performed, including D-dimer, fibrinogen, and platelet count, in patients with slow-flow vascular malformations treated with sirolimus. Laboratory values were assessed at three time points (presirolimus, 1-3 months postsirolimus, and last clinic visit). Clinical response, as defined by decreased pain and swelling, was extracted from the record. RESULTS: Thirty-five patients at our vascular anomalies center had been prescribed sirolimus between 2014 and 2017. Fifteen patients (12 combined slow-flow vascular malformations and three pure venous malformations) remained after excluding patients that did not have adequate records or a venous component to their vascular malformation. Patients who did not adhere to the treatment were also excluded. All 15 had elevated D-dimer levels prior to treatment and there was a statistically significant decrease in D-dimer levels following treatment with sirolimus. Symptomatic improvement of pain and swelling was reported after 3 months of starting sirolimus in 13/15 patients. CONCLUSION:
|
Authors | Joana M Mack, Bethany Verkamp, Gresham T Richter, Richard Nicholas, Kelly Stewart, Shelley E Crary |
Journal | Pediatric blood & cancer
(Pediatr Blood Cancer)
Vol. 66
Issue 10
Pg. e27896
(10 2019)
ISSN: 1545-5017 [Electronic] United States |
PMID | 31250546
(Publication Type: Journal Article)
|
Copyright | © 2019 Wiley Periodicals, Inc. |
Chemical References |
|
Topics |
- Adolescent
- Adult
- Blood Coagulation Disorders
(blood, drug therapy, etiology)
- Child
- Child, Preschool
- Female
- Humans
- Infant
- Male
- Retrospective Studies
- Sirolimus
(therapeutic use)
- Vascular Malformations
(blood, complications)
- Young Adult
|